← Eichor
Study identifier: NCT06428097 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Levothyroxine Supplementation for Heart Transplant Recipients

Condition: Heart Transplant Failure · Heart Transplant Infection  ·  Sponsor: University of California, San Francisco

PhasePhase 1
Planned participants97
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This will be a prospective, randomized study performed at a single tertiary referral academic medical center (University of California San Francisco, CA), evaluating the survival benefits of levothyroxine compared with no levothyroxine for patients who have undergone heart transplant. It will be double-blinded and placebo-control; participants will be randomized to receive levothyroxine or receive no levothyroxine.

This description comes directly from the study's public registry record.

Talk to the study team

Sarah Sullivan  ·  415-353-7083  ·  Sarah.sullivan2@ucsf.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of California, San FranciscoSan Francisco, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06428097